Completed PHASE3 INTERVENTIONAL NCT00035152

Study Comparing Weekly Taxol and Carboplatin vs Standard Taxol and Carboplatin Regimen for Stage IIIB or IV Non-Small-Cell Lung Cancer

A Multicenter, Randomized Trial for Stage IIIB or IV NSCLC Comparing Weekly Taxol(Paclitaxel) and Carboplatin(Paraplatin) Regimen Versus Standard Taxol and Carboplatin Administered Every Three Weeks, Followed by Weekly Taxol.

Sponsor: Bristol-Myers Squibb

Conditions Carcinoma, Non-Small-Cell Lung

Interventions Paclitaxel and carboplatin

Updated 6 times since 2017 Last updated: Sep 16, 2016 Started: Jun 30, 2000 Completion: Dec 31, 2004

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Carcinoma, Non-Small-Cell Lung, this trial is completed. The trial is conducted by Bristol-Myers Squibb and has accumulated 6 data snapshots since 2000. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Jun 2000

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bristol-Myers Squibb

Data source: Bristol-Myers Squibb

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albuquerque, United States , Amarillo, United States , Armonk, United States , Austell, United States , Austin, United States , Bismarck, United States , Boston, United States , Brooklyn, United States , Cary, United States , Cherry Hill, United States and 40 more locations